Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: Absolute bioavailability and effect of food

Biopharmaceutics and Drug Disposition

Volumn 19, Issue 6, 1998, Pages 351-356

  Tenero, David ^a,c   Martin, David ^b   Ilson, Bernard ^b   Jushchyshyn, John ^a   Boike, Steve ^b   Lundberg, David ^a   Zariffa, Nevine ^b   Boyle, Duane ^a   Jorkasky, Diane ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b PENN PRESBYTERIAN MEDICAL CENTER   (United States)

^c NONE   (United States)

Author keywords

Absolute bioavailability; Angiotensin II receptor antagonist; Eprosartan; Food effect; Pharmacokinetics

Indexed keywords

ANGIOTENSIN RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE; EPROSARTAN;

ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SOLUBILITY; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PLASMA CLEARANCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VOLUNTEER;

ACRYLATES; ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DIETARY FATS; FOOD-DRUG INTERACTIONS; HALF-LIFE; HUMANS; IMIDAZOLES; INJECTIONS, INTRAVENOUS; MALE; THIOPHENES;

EID: 0031822325     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199809)19:6<351::AID-BDD115>3.0.CO;2-V     Document Type: Article

References (13)

1. J.E. Sealy and J.H. Laragh, The renin-angiotensin-aldosterone system for normal regulation of blood pressure and sodium and potassium homeostasis. In Hypertension: Pathophysiology, Diagnosis and Management, J.H. Laragh and B.M. Brunner (Eds), Raven Press, New York, 1990, pp. 1287-1317.
2. R.N. Brogden, P.A. Todd and E.M. Sorkin, Captopril: an update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs, 36, 540-600 (1988).
3. A.H. Morice, R. Lowry, M.J. Brown and T. Higenbottam, Angiotensin-converting enzyme and the cough reflex. Lancet, ii, 1116-1118 (1987).
4. J.H. Laragh, Renin system blockade as a therapeutic strategy: past, present and future. Am. J. Hypertens., 4, 273S-274S (1991).
5. A. Manufo, Y. Christen, J. Nussberger, L. Shum, M. Borland, R. Lee, B. Waeber, J. Biollaz and H. Brunner, Drug concentration response relationship in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin. Pharmacol. Ther., 51, 513-521 (1992).
6. F. Steinhauslin, T. Buclin, P. Bouissou, I. Verejan, J. Nussberger, P. Tournadre, K. Vadiei, H. Brunner and J. Biollaz, Angiotensin II (AII) blockade effect of ANA-756 in normal volunteers. Clin. Pharmacol Ther., 55, 205 (1994).
7. B. Ilson, S. Boike, P. Audet, M. Freed, D. Everitt, L. Brown, N. Zariffa and D. Jorkasky, Renal hemodynamic effects of SK&F 108566, a nonpeptide selective angiotensin (AII) antagonist. Clin. Pharmacol Ther., 55, 206 (1994).
8. P.J. Cox, B.D. Bush, P.D. Gorycki, G.Y. Kuo, D. Kenworthy, D.W. Law, D. Murphy, P.C. Shardlow, A. Taylor, J.W. Upward, C.H. Compton and R.D. Murdoch, The metabolic fate of eprosartan in healthy volunteers. Exp. Tox. Pathol., 48, 75-82 (1996).
9. Data on File, SmithKline Beecham Pharmaceuticals, King of Prussia, PA.
10. B. Ilson, D. Tenero, S. Knox, S. Boike, P. Audet, M. Freed, D. Everitt, L. Brown, D. Boyle and D. Jorkasky, Food significantly increases the oral bioavailability of SK&F 108566. Clin. Pharmacol Ther., 55, 167 (1994).
11. D.E. Lundberg, Jr., C.R. Person, S. Knox, and M. Cyronak, Determination of SK&F 108566 in human plasma by solid-phase extraction cleanup and reversed-phased high-performance liquid chromatography. J. Chromatogr. B, (in press).
12. W.L. Chiou, Critical evaluation of the potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level time curve. J. Pharmacokinet. Biopharm., 6, 539-547 (1978).
13. V.W. Steinijans and E. Diletti, Statistical analysis of bioavailability studies: parametric and non-para metric confidence intervals. Eur. J. Clin. Pharmacol., 24, 127-136 (1983).